---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-077372"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:45:17.732144+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Carisma terminates Novartis manufacturing deal for CT-0508; pays $4M fee, suspends Phase 1 enrollment

## Summary
- Terminated Manufacturing and Supply Agreement with Novartis for CT-0508; effective July 31, 2024.
- Will pay $4.0M termination fee to Novartis in Q3 2024, with potential credit if Substitute Product transferred by Dec 31, 2024.
- Suspends enrollment of new patients in Phase 1 trial for CT-0508 to focus ex vivo oncology on follow-on candidate CT-0525.
- Revised operating plan narrows pipeline, prioritizing CT-0525 over CT-0508.

## SEC filing metadata
- accession: 0001104659-24-077372
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465924077372/0001104659-24-077372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465924077372/tm2418685d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-077372
- JSON: https://secwatch.observer/filing/0001104659-24-077372.json
- Plain text: https://secwatch.observer/filing/0001104659-24-077372.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.